Alok A Khorana
Overview
Explore the profile of Alok A Khorana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
250
Citations
9902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sloan A, Gordillo A, Kennemer A, Khorana A, Horbinski C, Kaelber D, et al.
medRxiv
. 2025 Jan;
PMID: 39830282
Background: Venous thromboembolisms (VTE's) are the second leading cause of death in cancer patients. While previous analyses have demonstrated VTE rates are greater in GBM patients using smaller patient cohorts...
2.
Cloyd J, Sarna A, Arango M, Bates S, Bhutani M, Bloomston M, et al.
JAMA Surg
. 2024 Dec;
160(2):172-180.
PMID: 39630427
Importance: Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and...
3.
Chapman Jr W, Gorgun E, Yilmaz S, Rosen D, Valente M, Valente M, et al.
Dis Colon Rectum
. 2024 Nov;
68(2):190-198.
PMID: 39527827
Background: Among patients with rectal cancer treated with total neoadjuvant therapy, it is unclear whether early, postinduction restaging is associated with final tumor response. If so, interim restaging may alter...
4.
Yilmaz S, Liska D, Conces M, Tursun N, Elamin D, Ozgur I, et al.
Dis Colon Rectum
. 2024 Sep;
68(1):60-68.
PMID: 39260428
Background: Total neoadjuvant therapy in the treatment of stage II and III rectal cancer involves the administration of either induction or consolidation chemotherapy with chemoradiation before surgery. Total neoadjuvant therapy...
5.
Jayakrishnan T, Baca Y, Xiu J, Patel M, Weinberg B, Lou E, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400138.
PMID: 39102632
Purpose: Early-onset biliary tract cancer (eoBTC) is among the fast-growing subset of early-onset cancers, yet little is known about its biology. We sought to identify novel molecular characteristics of eoBTC...
6.
Jayakrishnan T, Sangwan N, Barot S, Farha N, Mariam A, Xiang S, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):146.
PMID: 39020083
The incidence of early-onset colorectal cancer (eoCRC) is rising, and its pathogenesis is not completely understood. We hypothesized that machine learning utilizing paired tissue microbiome and plasma metabolome features could...
7.
Tsai Y, Nair K, Barot S, Xiang S, Kamath S, Melas M, et al.
J Natl Cancer Inst
. 2024 Jun;
116(10):1645-1653.
PMID: 38902947
The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early-onset CRC [EOCRC]) has substantially increased, and yet the etiology and molecular mechanisms underlying this alarming rise remain...
8.
Linder M, Ekbom A, Brobert G, Vogtlander K, Balabanova Y, Becattini C, et al.
J Thromb Thrombolysis
. 2024 May;
57(6):973-983.
PMID: 38735015
Background: Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk. Objectives: To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban...
9.
Liz-Pimenta J, Tavares V, Gramaca J, Rato J, Menezes M, Baleiras M, et al.
J Thromb Thrombolysis
. 2024 Apr;
57(5):805-814.
PMID: 38643312
Introduction: Cancer-associated thrombosis (CAT) is a significant concern among patients with malignant diseases, leading to increased mortality. While current guidelines recommend primary thromboprophylaxis for venous thromboembolism (VTE) in medium-to-high-risk outpatients,...
10.
Jayakrishnan T, Mariam A, Farha N, Rotroff D, Aucejo F, Barot S, et al.
Sci Rep
. 2024 Feb;
14(1):4294.
PMID: 38383634
Deleterious effects of environmental exposures may contribute to the rising incidence of early-onset colorectal cancer (eoCRC). We assessed the metabolomic differences between patients with eoCRC, average-onset CRC (aoCRC), and non-CRC...